Has the potential for genotoxicity and carcinogenicity.
Skip to main content
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- Indications: Chagas disease (trypanosomiasis) in pediatric patients aged 2–12 years
- Class: Antibiotic, Antibiotic; nitroimidazole, Antimicrobial
- Half-life: 13 hours
- FDA Approval Date: 08/29/2017
- Clinically important, potentially hazardous interactions with:
Disulfiram - Pregnancy: Can cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 04/21/2026
